GET DAILY SIGNALSEcolab (ECL) Delivers 5% EPS Growth in Q3 with Revenue Beat
Key Takeaways
- Adjusted diluted earnings per share (EPS) rose 5% year over year to $2.18, matching analyst consensus estimates.
- Revenue climbed 13% year over year to $4.69 billion, slightly ahead of consensus, while organic sales grew 7%.
- Reported (GAAP) diluted EPS was $1.95, down 5% from the prior-year quarter, reflecting acquisition-related costs.
- Organic operating income margin expanded 70 basis points (bps) to 19.6%, keeping Ecolab on track toward its 20% margin target for 2027.
- Full-year 2026 adjusted EPS guidance was narrowed to $8.10–$8.20, and fourth-quarter adjusted EPS guidance was set at $2.13–$2.23.
- For more detail on Ecolab's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages for the latest insights.
- Discover automated trading strategies and market opportunities with Trending AI Robots.
Earnings Context and Why It Matters
Ecolab's quarterly results offer a read on broad industrial and commercial demand, given the company's reach across water treatment, hygiene, cleaning, and infection prevention for customers in food, healthcare, hospitality, and manufacturing. The third-quarter report is especially significant because it shows whether Ecolab's growth engines — Global High-Tech, Life Sciences, Pest Elimination, and digital solutions — can sustain momentum while rising commodity costs and geopolitical disruptions, including customer interruptions in the Middle East, pressure the broader operating environment. With management pursuing a 20% adjusted operating margin target by 2027, investors are watching closely whether pricing gains and productivity improvements can offset cost inflation and the early integration effects of recent acquisitions such as Ovivo Electronics and CoolIT. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, Ecolab reported adjusted diluted EPS of $2.18, up 5% from $2.08 a year earlier and in line with the consensus estimate. Reported (GAAP) diluted EPS was $1.95, down 5% from $2.05 in the prior-year period, reflecting special gains and charges tied primarily to acquisition and integration costs.
Net sales rose 13% year over year to $4.69 billion, slightly ahead of the Zacks consensus estimate of $4.67 billion. Organic sales increased 7%, driven by a 5% contribution from pricing and a 2% increase in volume. Ecolab Digital sales jumped 34% to $129 million, while Global Life Sciences delivered 17% organic sales growth on continued share gains in bioprocessing, personal care, and purification.
Reported gross margin contracted 70 bps to 44.1%, largely due to acquisition mix, while organic gross margin improved 10 bps to 44.9% as pricing offset higher commodity costs. Adjusted operating income rose 13.6% to $893.4 million, and organic operating income margin expanded 70 bps to 19.6%.
Market Reaction and Investor Sentiment
ECL shares closed at $288.89 on October 27, 2026, with the stock up roughly 4% over the prior three months and nearly 8% over the trailing 12 months. The in-line EPS result and modest revenue beat did not produce a dramatic post-earnings swing, suggesting investors had already priced in steady execution. The narrowed full-year guidance — a range of $8.10 to $8.20 versus a prior $8.05 to $8.25 — reinforced confidence in the company's trajectory without a major upside surprise. Sentiment remains supported by accelerating organic sales growth and broad-based margin expansion, though acquisition-related amortization and financing costs from the CoolIT deal continue to weigh on near-term adjusted EPS growth.
Forward Outlook and Key Factors to Monitor
Looking ahead, Ecolab guided to fourth-quarter 2026 reported sales growth of 12% to 14%, organic sales growth of 6% to 7%, and adjusted diluted EPS of $2.13 to $2.23. For the full year, management narrowed its adjusted EPS outlook to $8.10–$8.20, reflecting 8% to 9% growth versus 2025 despite an approximate six-percentage-point headwind from CoolIT acquisition-related amortization and financing costs.
Investors should monitor several factors in the coming quarters. First, whether pricing power can continue to offset rising commodity costs and whether organic gross margin holds near 44.9%. Second, the pace of integration for the Ovivo Electronics and CoolIT acquisitions, which have diluted reported margins but are expected to strengthen long-term growth. Third, demand signals in Global High-Tech and Life Sciences, which have been standout performers tied to microelectronics, data centers, and bioprocessing.
Finally, watch progress toward the 20% adjusted operating margin target for 2027, with management citing continued pricing execution, productivity gains, and a favorable mix shift toward higher-margin digital and life-sciences offerings as key drivers.
Exploring AI Tools for Portfolio Insights
In my view, tools like Tickeron’s AI Screener have become useful for quickly scanning the specialty chemicals sector and comparing names like Ecolab against peers on fundamentals and technical signals. I’ve found it helpful when reviewing quarterly results to cross-check how a stock’s performance stacks up against broader industry trends without spending hours on manual analysis. This kind of filtering supports a more disciplined approach to building and monitoring watchlists over time.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for ECL turns positive, indicating new upward trend
ECL saw its Momentum Indicator move above the 0 level on October 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned positive. In 54 of the 81 cases, the stock moved higher in the following days. The odds of a move higher are at 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ECL just turned positive on October 05, 2026. Looking at past instances where ECL's MACD turned positive, the stock continued to rise in 31 of 50 cases over the following month. The odds of a continued upward trend are 62%.
ECL moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ECL crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 64%.
Following a +1.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where ECL advanced for three days, in 173 of 330 cases, the price rose further within the following month. The odds of a continued upward trend are 52%.
Bearish Trend Analysis
The 10-day RSI Indicator for ECL moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator moved out of overbought territory. In 23 of the 48 cases, the stock moved lower in the following days. This puts the odds of a move lower at 48%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 68 cases where ECL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ECL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
The Aroon Indicator for ECL entered a downward trend on October 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ECL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 49 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock slightly better than average.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.054) is normal, around the industry mean (2.372). P/E Ratio (38.519) is within average values for comparable stocks, (-17.554). Projected Growth (PEG Ratio) (2.525) is also within normal values, averaging (1.548). Dividend Yield (0.010) settles around the average of (0.040) among similar stocks. P/S Ratio (4.621) is also within normal values, averaging (48.960).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of cleaning, sanitizing, pest control, maintenance and repair products and services
Industry ChemicalsSpecialty
Advertisement